

1
2
3
4
5
6
7
8 UNITED STATES DISTRICT COURT
9 SOUTHERN DISTRICT OF CALIFORNIA
10

11 JEFF RIHN, individually and on
12 behalf of all others similarly
13 situated,
14 Plaintiff,
15 v.
16 ACADIA PHARMACEUTICALS
17 INC., ULI HACKSELL AND
18 STEPHEN R. DAVIS,
19 Defendants.

Case No.: 15-cv-00575 BTM-DHB

**ORDER GRANTING PLAINTIFFS'
MOTION FOR FINAL APPROVAL
OF CLASS ACTION SETTLEMENT
AND MOTION FOR ATTORNEYS'
FEES AND EXPENSES**

ECF NOS. 75, 76

20 Plaintiffs have filed a Motion for Final Approval of the Class Action Settlement
21 (ECF No. 75) and a Motion for Attorneys' Fees and Expenses (ECF No. 76). On
22 January 8, 2018, the Court held a hearing on the motions. For the reasons
23 discussed below, Plaintiffs' motions are **GRANTED**.

24 **I. PROCEDURAL BACKGROUND**

25 On November 16, 2015, Lead Plaintiffs, Paul and Sharyn Levine, filed a
26 Consolidated Class Action Complaint ("CCAC") against Defendants Acadia
27 Pharmaceuticals Inc. ("Acadia"), Uli Hacksell, and Stephen R. Davis. (ECF No.
28

1 43). The CCAC asserted claims for violations of **(1)** section 10(b) of the Securities
2 Exchange Act, 15 U.S.C. § 78j(b), and Rule 10b-5 and **(2)** section 20(a) of the
3 Securities Exchange Act. *Id.* The claims were premised on allegations that
4 Defendants knowingly and recklessly made materially false and misleading
5 statements regarding the timing and status of Acadia's New Drug Application
6 ("NDA") for its lead product candidate, Nuplazid (pimavanserin). *Id.* These false
7 and misleading statements allegedly artificially inflated stock prices of Acadia
8 between November 10, 2014 and March 11, 2015 (the "Class Period"). *Id.*

9 On September 19, 2016, the Court denied Defendants' motion to dismiss the
10 CCAC. (ECF No. 56). On November 4, 2016, the Court granted a joint motion to
11 stay the action pending private mediation. (ECF No. 63). The parties filed a joint
12 motion for settlement on March 13, 2017 (ECF No. 67) and the Court issued a
13 preliminary order approving the settlement on June 9, 2017 (ECF No. 71).

14 **II. DISCUSSION**

15 **A. Motion for Final Approval**

16 **1. Class Certification**

17 Plaintiffs seek final certification of the Settlement Class, defined as: lead
18 Plaintiffs as well as all Persons who purchased or otherwise acquired the publicly
19 traded common stock and/or call options of ACADIA in the United States on the
20 NASDAQ Global Select Market during the Class Period and who allege to have
21 been damaged thereby.

22 Excluded from the Class are Defendants and members of their immediate
23 families; any firm, trust, partnership, corporation, officer, director, or other
24 individual or entity in which a Defendant has a controlling interest or which is
25 related to or affiliated with any of the Defendants, and the legal representatives,
26 heirs, successors-in-interest or assigns of such excluded Persons; and the Judge
27 and Magistrate Judge to whom the Action is assigned, and any member of those
28

1 Judges' staff or immediate families.¹ Also excluded from the Class is any
2 Person who properly excluded himself, herself, or itself by filing a valid and timely
3 request for exclusion in accordance with the requirements set forth in the
4 Settlement Notice. The Class Period is defined as the period from November 10,
5 2014, through and including March 11, 2015, both dates inclusive.

6 To certify a settlement class, the requirements of Rule 23 must generally
7 be satisfied. *Hanlon v. Chrysler Corp.*, 150 F.3d 1011, 1019 (9th Cir. 1998).
8 However, the Court need not inquire whether the case, if tried, would present
9 management problems. *Amchem Prods., Inc. v. Windsor*, 521 U.S. 1, 613
10 (1997).

11 Rule 23(a) sets forth four prerequisites for class certification: (1)
12 numerosity; (2) commonality; (3) typicality; and (4) adequacy of representation.
13 The Court finds that all four of these requirements have been satisfied.

14 The numerosity requirement is satisfied if “the class is so numerous that
15 joinder of all members is impracticable.” Fed. R. Civ. P. 23(a)(1). The proposed
16 class is numerous, consisting of 27,830 Class Members.

17 There are common questions of fact and law concerning whether
18 Defendants made materially false and misleading statements regarding the
19 status and timing of Acadia’s NDA for Nuplazid (pimavanserin). Plaintiffs’ claims
20 are typical because they allege that they purchased publicly traded securities of
21 Acadia during the Class Period and were damaged because Defendants
22 artificially inflated the price of Acadia securities through their dissemination of
23 false and misleading statements about the NDA.

24
25
26
27 ¹ Under 28 U.S.C. § 455(b)(5)(iii), any judge of the United States shall disqualify himself if he or his spouse, or a
28 person within the third degree of relationship to either of them, or the spouse of such a person is known by the
judge to have an interest that could be substantially affected by the outcome of the proceeding. The Court
amends the Settlement Class definition to exclude such individuals as well.

1 It appears that Plaintiffs and their counsel will fairly and adequately protect
2 the interests of the class. They have vigorously prosecuted the case thus far and
3 it does not appear that there are any conflicts of interest.

4 In addition to satisfying the requirements of Rule 23(a), a proposed class
5 must qualify for certification under one of the categories in Rule 23(b). Plaintiffs
6 seek certification under Rule 23(b)(3). Certification is proper under Rule 23(b)(3)
7 if “the court finds that the questions of law or fact common to class members
8 predominate over any questions affecting only individual members, and that a
9 class action is superior to other available methods for fairly and efficiently
10 adjudicating the controversy.”

11 The predominance inquiry “tests whether proposed classes are sufficiently
12 cohesive to warrant adjudication by representation” and “focuses on the
13 relationship between the common and individual issues.” *Hanlon*, 150 F.3d at
14 1022 (internal quotation marks and citation omitted). “When common questions
15 represent a significant aspect of the case and they can be resolved for all
16 members of the class in a single adjudication, there is a clear justification for
17 handling the dispute on a representative rather than on an individual basis.” 7AA
18 Wright & Miller, Federal Practice and Procedure § 1778 (3d ed. 2011). When
19 one or more of the central issues in the action are common to the class and can
20 be deemed to predominate, certification may be proper under Rule 23(b)(3) even
21 though other important matters, such as damages or affirmative defenses, will
22 have to be tried separately. *Id.*

23 Common issues predominate in this litigation. The central inquiry in this
24 case is whether Defendants violated the Securities Exchange Act by
25 disseminating materially false and misleading information regarding the status
26 and timing of Acadia’s NDA for Nuplazid (pimavanserin), leading to artificially
27 inflated prices of Acadia’s publicly traded securities.

28 In addition, class treatment is the appropriate vehicle to resolve this

1 controversy. Pursuant to Rule 23(b)(3), the Court should consider four non-
2 exclusive factors when considering whether class action is a superior method of
3 adjudication, including: (1) the class members' interest in individual litigation, (2)
4 other pending litigation, (3) the desirability of concentrating the litigation in one
5 forum, and (4) difficulties with the management of the class action.

6 Here, the damages for each class member would be small. Therefore,
7 class members would have little motivation to pursue individual cases.
8 Furthermore, due to the common issues in this case, it is desirable to litigate the
9 claims in one forum to ensure consistency of rulings and findings. The parties
10 are unaware of any competing litigation, and the Court need not be concerned
11 regarding any difficulties with management of the class action due to this
12 settlement.

13 In sum, the Court finds that the requirements of Rule 23(a) have been
14 satisfied and certifies the Settlement Class under Rule 23(b)(3).

15 **2. Fairness, Reasonableness, and Adequacy of the** 16 **Settlement**

17 **a. Terms of the Settlement**

18 The settlement provides for a gross payment of \$2,925,000. The settlement
19 amount will be paid into escrow and, after paying attorneys' fees and expenses
20 approved by the Court, and other costs of settlement, the net settlement amount
21 will be distributed among the class members with recognized losses who timely
22 submit valid Proof of Claim and Release Forms.

23 **b. Legal Standard**

24 Before approving a class action settlement, the court must determine
25 whether the proposed settlement is fair, reasonable, and adequate. Fed. R. Civ.
26 P. 23(e)(2). In reaching this determination, courts consider a number of factors,
27 including: (1) the strength of the plaintiff's case; (2) the risk, expense, complexity,
28 and likely duration of further litigation; (3) the risk of maintaining class action status

1 throughout the trial; (4) the amount offered in settlement; (5) the extent of discovery
2 completed and the stage of the proceedings; (6) the experience and views of
3 counsel; (7) the presence of a governmental participant; and (8) the reaction of the
4 class members to the proposed settlement. *Churchill Vill., L.L.C. v. Gen. Elec.*, 361
5 F.3d 566, 575 (9th Cir.2004).

6 When a settlement agreement is negotiated prior to formal class certification,
7 the court must also scrutinize the settlement for evidence of collusion or other
8 conflicts of interest. *In re Bluetooth Headset Products Liability Lit.*, 654 F.3d 935,
9 946-47 (9th Cir. 2011). Signs of collusion include: (1) when counsel receive a
10 disproportionate distribution of the settlement; (2) when the parties negotiate a
11 "clear sailing" arrangement that provides for the payment of attorney's fees
12 separate and apart from class funds; and (3) when the parties arrange for fees not
13 awarded to revert to defendants rather than to be added to the class fund. *Id.* at
14 947.

15 **c. Strength of Plaintiffs' Case and Risk, Complexity,**
16 **Expense, and Duration of Litigation**

17 Plaintiffs would face substantial risks in continued litigation, which would
18 undoubtedly be time-consuming and costly. Defendants maintain that "they did
19 not make any actionable misstatements or omissions during the Class Period, they
20 did not act with scienter, and Lead Plaintiffs will be unable to prove that their and
21 the Class's losses arise out of Defendants' alleged misconduct." Faruqi Decl. ¶ 43.
22 Specifically, Defendants contend that (i) "all of the statements in the [CCAC] are
23 either protected by the PSLRA safe-harbor or are inactionable corporate
24 optimism," (ii) "the [CCAC] does not include any particularized facts that the NDA
25 was not on track to be submitted in March 2015," (iii) "the scienter allegations in
26 the [CCAC] are nothing more than speculation as Lead Plaintiffs cannot show that
27 Defendants had access to information indicating that the NDA was not on track to
28 be submitted by March 2015," (iv) "Defendants' lack of stock sales and large

1 personal holdings negate an inference of scienter,” and (v) “Lead Plaintiffs cannot
2 establish loss causation because the stock drop on March 12, 2015 was due to the
3 realization that the Company would not be acquired, not due to the Second Delay.”
4 *Id.*

5 Further, “Lead Plaintiffs would have faced a great deal of difficulty in
6 obtaining the necessary documents and depositions” as “the events alleged in the
7 [CCAC] took place as long as four and a half years ago, and the company is under
8 new management.” *Id.* ¶ 45. “[T]he relevant documents may have been misplaced,
9 former employees may be difficult to locate, and the memories of the parties
10 involved in the actions alleged in the [CCAC] may have faded.” *Id.* “The complexity
11 of the allegations would have required the retention of additional FDA experts,
12 serving third party document subpoenas, and countless depositions.” *Id.*

13 **d. Amount Offered in Settlement**

14 The settlement amount of \$2,925,000 “represents approximately 15% of the
15 damages recoverable by Class Members in the Action.” Faruqi Decl. ¶ 80.
16 Accordingly, the benefit provided to the class members is substantial. *See In re*
17 *Cendant Corp. Litig.*, 264 F.3d 201, 241 (3d Cir. 2001) (noting that recoveries for
18 class action securities litigation typically range from 1.6% to 14% of claimed
19 damages).

20 When the balance remaining in the net settlement fund is *de minimus*, the
21 remaining balance will be distributed to the Investor Protect Trust. The *cy pres*
22 doctrine allows a court to distribute unclaimed or non-distributable portions of a
23 class action settlement fund to indirectly benefit the entire class. *Six Mexican*
24 *Workers v. Ariz.Citrus Growers*, 904 F.2d 1301, 1305 (9th Cir. 1990). When
25 employing the *cy pres* doctrine, unclaimed funds should be put to their next best
26 use, e.g., for “the aggregate, indirect, prospective benefit of the class.” *Nachshin*
27 *v. AOL, LLC*, 663 F.3d 1034, 1038 (9th Cir. 2011).

28 The Ninth Circuit has held that *cy pres* distribution must be “guided by (1)

1 the objectives of the underlying statute(s); and (2) the interests of the silent class
2 members.” *Six Mexican Workers*, 904 F.2d at 1307. A *cy pres* distribution is an
3 abuse of discretion if there is “no reasonable certainty” that any class member
4 would benefit from it. *Dennis v. Kellogg Co.*, 697 F.3d 858, 865 (9th Cir. 2012).

5 The Investor Protection Trust is a nonprofit organization with the primary
6 mission to provide independent objective information needed by consumers to
7 make informed investment decisions. The Court finds the designated *cy pres*
8 recipient appropriate.

9 **e. Stage of Proceedings and Experience and Views**
10 **of Counsel**

11 Lead Counsel, on behalf of Lead Plaintiffs, conducted “an extensive
12 investigation into the facts alleged in the Action, including reviewing FDA
13 documents, press releases, SEC filings, conference call transcripts, and analyst
14 reports.” Faruqi Decl. ¶ 38. Prior to settlement, the Court had denied Defendants’
15 motion to dismiss but had not yet ruled on Defendants’ motion for reconsideration
16 of the order denying the motion to dismiss.

17 On December 6, 2016, the parties met with a “highly respected and
18 experienced securities litigation mediator, for an arm’s-length mediation session.”
19 *Id.* ¶ 40. “In advance of the mediation session, both sides submitted and
20 exchanged lengthy mediation briefs outlining their respective analyses of the
21 claims and defenses, and several exhibits.” *Id.* During the session itself, “the
22 parties extensively debated the strengths and weaknesses of Lead Plaintiffs’
23 claims and the defenses available to Defendants.” *Id.* The parties are in a position
24 to accurately assess the strengths and weakness of their respective positions. In
25 addition, Lead Counsel, a law firm with substantial experience litigating securities
26 class action lawsuits, is of the opinion that the settlement is fair, reasonable, and
27 adequate. *Id.* ¶ 56.

1 **f. Reaction of the Class Members**

2 The reaction of Class Members has been positive. No objections have been
3 filed and there has only been one request for exclusion. Cavallo Decl. ¶¶ 11, 12.
4 In addition, no objections were filed after notification to appropriate federal and
5 state officials pursuant to 28 U.S.C. § 1715(b). No objectors appeared at the final
6 approval hearing.

7 **g. Lack of Collusion**

8 Because this settlement was reached prior to class certification, the Court
9 examines the Settlement for evidence of collusion. *Bluetooth*, 654 F.3d at 946-47.
10 There is no indication of collusion. Lead Counsel seeks a fee award totaling 25%
11 of the Settlement Fund. This percentage of recovery is typical and does not
12 represent a disproportionate distribution of the settlement to counsel. *Six Mexican*
13 *Workers*, 904 F.2d at 1311.

14 Additionally, there is no “clear sailing” provision here, as the attorneys’ fees
15 are to be paid only out of the Settlement Fund, and at a rate approved by the Court.

16 Moreover, the parties engaged in extensive settlement negotiations and
17 participated in mediation sessions with Robert Meyer, Esq. The history of the case
18 as well as the substantial benefit provided to the Class by the Settlement indicate
19 there has been no collusion.

20 **h. Notice to the Class**

21 Rule 23(c)(2)(B) provides that the Court must direct to class members “the
22 best notice that is practicable under the circumstances, including individual notice
23 to all members who can be identified through reasonable effort.” It appears that
24 the best notice practicable has been given.

25 Here, Kurtzman Carson Consultants LLC (“KCC”), pursuant to the
26 Preliminary Approval Order, mailed the Settlement Notice to 27,830 potential Class
27 Members beginning on June 30, 2017. Faruqi Decl. ¶ 60. The Settlement Notice
28 and the Proof of Claim form were also made available on

1 www.AcadiaSecuritiesSettlement.com, which has been visited 7,463 times as of
2 August 23, 2017. *Id.* ¶ 62. The Publication Notice was published in *Investor's*
3 *Business Daily* and posted by *PR Newswire* on July 10, 2017. *Id.* ¶ 60. Additionally,
4 KCC set up a toll-free telephone helpline to accommodate potential Class
5 Members who had questions regarding the Settlement. *Id.* ¶ 61. The help line
6 received 90 calls as of August 23, 2017. *Id.*

7 The Settlement Notice included: (i) the case caption, (ii) a description of the
8 claims, (iii) a description of the Settlement Class, (iv) the names of Lead Counsel,
9 (v) the amount of attorneys' fees and expenses that will be requested, (vi) the Final
10 Fairness Hearing date, (vii) the Class Members' opportunity to appear at the Final
11 Fairness Hearing, (viii) the deadline for filing objections to and exclusions from the
12 Settlement, (ix) the consequences of exclusion, (x) the consequences of remaining
13 a Class Member, (xi) the manner in which to obtain more information, and (xii)
14 directions on how to access the case docket. See Cavallo Decl. Ex. A.

15 i. Final Approval

16 For the reasons discussed above, the Court finds that the Settlement is fair,
17 reasonable, and adequate. Therefore, the Court grants final approval of the
18 Settlement.

19
20
21
22
23
24
25
26
27
28

1 **B. Motion for Attorneys' Fees and Expenses**

2 **1. Attorneys' Fees**

3 Plaintiffs seek attorneys' fees in the amount of \$731,250 – 25% of the
4 anticipated \$2,925,000 Settlement Fund.

5 The Ninth Circuit has established 25% of a common fund as a benchmark
6 award for attorney's fees. *Six Mexican Workers*, 904 F.2d at 1311. The court may
7 depart from this benchmark percentage if special circumstances indicate that the
8 percentage recovery would be either too small or too large. *Id.* The court's
9 selection of the benchmark or any other rate must be supported by findings that
10 take into account all of the circumstances of the case. *Vizcaino v. Microsoft Corp.*,
11 290 F.3d 1043, 1047 (9th Cir. 2002). Such factors include, but are not limited to:
12 (1) the results achieved; (2) the risk involved in the litigation; (3) incidental or
13 nonmonetary benefits conferred by the litigation; and (4) financial burden of the
14 case on counsel. *Id.* at 1049-50.

15 The Court finds that 25% of the Settlement Fund is an appropriate award in
16 this case. This conclusion is based on the quality of representation by counsel,
17 the excellent results achieved for the class, and the real risks of continued
18 litigation. There does not appear to be a basis for departing from the benchmark
19 percentage.

20 Application of the "lodestar method" may provide a useful "cross-check" as
21 to the reasonableness of a given percentage award. *Vizcaino*, 290 F.3d at 1050.
22 Courts commonly use a rough calculation of the lodestar as a cross-check.
23 *Hopkins v. Stryker Sales Corp.*, 2013 WL 496358, at *4 (N.D. Cal. Feb. 6 2013).

24 Here, a rough calculation of the lodestar comes to \$709,630. Mem. of P. &
25 A. in Support of Attorneys' Fees Mot. at 13. Based on the lodestar, the multiplier
26 is 1.03. Courts have "routinely enhanced the lodestar to reflect the risk of non-
27 payment in common fund cases." *Vizcaino v. Microsoft Corp.*, 142 F. Supp. 2d
28 1299, 1305 (W.D. Wash. 2001). "To restrict Class Counsel to the hourly rates they

1 customarily charge for non-contingent work – where payment is assured – would
2 deprive them of any financial incentive to accept contingent-fee cases which may
3 produce nothing. Courts have therefore held that counsel are entitled to a multiplier
4 for risk.” *Id.*

5 Multipliers of 1 to 4 are commonly found to be appropriate in common fund
6 cases. *Vizcaino*, 290 F.3d at 1051 n. 6. Accordingly, the 1.03 multiplier is within
7 the range of reasonableness. Therefore, the lodestar cross-check supports the
8 reasonableness of the requested fees of \$731,250.

9 **2. Expenses**

10 Lead Counsel seeks \$75,534.64 in costs. These costs were for expert and
11 investigator fees, mediation fees, filing fees, electronic research, photocopying,
12 postage, meals, travel, and lodging. See Supp. Decl. Faruqi in Support of
13 Attorneys’ Fee Mot. These are the types of expenses routinely charged to paying
14 clients. See *In re Omnivision Tech.*, 559 F. Supp. 2d 1036, 1048 (N.D. Cal. 2008)
15 (explaining that class counsel “may recover their reasonable expenses that would
16 typically be billed to paying clients in non-contingency matters”).

17 However, the Court does not consider the \$988.63 in Lexis Nexis research
18 fees to be a qualified expense. Fees for the subscription service would have been
19 incurred regardless of whether research was done for this case and therefore
20 should be properly considered as part of the firm’s overhead.

21 Therefore, the Court grants Lead Counsel’s request for reimbursement of
22 expenses in the amount of \$74,546.01.

23 **3. Incentive Fee Award**

24 Plaintiffs seek an incentive award of \$2,500.00 for Lead Plaintiff, Sharyn
25 Levine.

26 The Court may, in its discretion, award incentive or service awards to named
27 plaintiffs to “compensate class representatives for work done on behalf of the
28 class, to make up for financial or reputational risk undertaken in bringing the action,

1 and, sometimes, to recognize their willingness to act as a private attorney general.”
2 *Rodriguez v. West Publishing Corp.*, 563 F.3d 948, 958-59 (9th Cir. 2009). District
3 courts must carefully scrutinize incentive awards to ensure that they do not
4 undermine the adequacy of the class representatives. *Radcliffe v. Experian*
5 *Information Solutions, Inc.*, 715 F.3d 1157, 1165 (9th Cir. 2013).


6 Lead Counsel states that over the past two and a half years, Plaintiff has (i)
7 engaged in numerous communications with Lead Counsel, (ii) participated in the
8 litigation and provided input into the prosecution of the case, (iii) reviewed
9 documents filed in this Action, including the CCAC and motion to dismiss briefing,
10 (iv) stayed fully informed of the status of the case, and (v) consulted with counsel
11 and provided input on the mediation and settlement negotiations. Faruqi Decl. ¶
12 97. In light of the work Plaintiff has done on behalf of the class, the requested
13 incentive award is reasonable and is approved.

14 III. CONCLUSION

15 For the reasons set forth above, Plaintiffs’ Motion for Final Approval of the
16 Class Action Settlement is **GRANTED**. Plaintiffs’ Motion for Attorneys’ Fees and
17 Expenses is also **GRANTED**. The Court grants attorney’s fees in the amount of
18 \$731,250, expenses in the amount of \$74,546.01, and an incentive award of
19 \$2,500.

20
21 **IT IS SO ORDERED.**

22
23
24 Dated: January 22, 2018

25 
26 Barry Ted Moskowitz, Chief Judge
27 United States District Court
28